4593
HEALIOS K.K.
ヘリオス
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- IFRS
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Dec 2021
41
Dec 2022
90
Dec 2023
121
Dec 2024
560
Dec 2025
104
Operating profit(million JPY)
Dec 2021
-5,384
Dec 2022
-5,179
Dec 2023
-3,379
Dec 2024
-2,843
Dec 2025
-3,340
Operating profit margin(%)
Dec 2021
-13,131.71
Dec 2022
-5,754.44
Dec 2023
-2,792.56
Dec 2024
-507.68
Dec 2025
-3,211.54
Profit before tax(million JPY)
Dec 2021
-4,462
Dec 2022
-5,330
Dec 2023
-3,626
Dec 2024
-4,061
Dec 2025
-2,126
Profit(million JPY)
Dec 2021
-4,910
Dec 2022
-5,169
Dec 2023
-3,823
Dec 2024
-4,235
Dec 2025
-2,217
Total assets(million JPY)
Dec 2021
23,971
Dec 2022
15,033
Dec 2023
15,155
Dec 2024
14,191
Dec 2025
17,054
Cash and cash equivalents(million JPY)
Dec 2021
15,126
Dec 2022
7,247
Dec 2023
6,722
Dec 2024
3,672
Dec 2025
5,679
Cash flows from operating activities(million JPY)
Dec 2021
-5,089
Dec 2022
-4,601
Dec 2023
-2,822
Dec 2024
-1,817
Dec 2025
-3,165
Cash flows from investing activities(million JPY)
Dec 2021
-736
Dec 2022
-909
Dec 2023
-1,121
Dec 2024
-1,418
Dec 2025
-1,114
Cash flows from financing activities(million JPY)
Dec 2021
6,988
Dec 2022
-2,502
Dec 2023
3,337
Dec 2024
77
Dec 2025
6,335
Return on equity(%)
Dec 2021
-59.6
Dec 2022
-79.4
Dec 2023
-92.8
Dec 2024
-143.1
Dec 2025
-63.8
Equity ratio(%)
Dec 2021
36
Dec 2022
29.2
Dec 2023
25.4
Dec 2024
14.5
Dec 2025
28.7
Earnings per share(JPY per share)
Dec 2021
-93.36
Dec 2022
-90.67
Dec 2023
-56.22
Dec 2024
-47.86
Dec 2025
-20.59
Net assets per share(JPY per share)
Dec 2021
156.65
Dec 2022
69.33
Dec 2023
51.73
Dec 2024
22.86
Dec 2025
42.26
Dividend per share(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Payout ratio(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.